SIGMAPHARM LABORATORIES LLC
SIGMAPHARM LABORATORIES LLC (United States) holds 5 active US FDA Type II Drug Master Files, has DMF or CEP filings on record for 3 active ingredients and is linked to 1 FDA-registered manufacturing site. 15 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “SIGMAPHARM LABORATORIES LLC: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/sigmapharm-laboratories-llc
Overview
SIGMAPHARM LABORATORIES LLC is an active pharmaceutical ingredient (API) supplier with 5 active FDA Type II Drug Master Files, covering AMORPHOUS ADEFOVIR DIPIVOXIL (11.6% COPOVIDONE DISPERSION); AMORPHOUS DOFETILIDE; APIXABAN AMORPHOUS (6.58%); ASENAPINE MALEATE AMORPHOUS (31.2%) PREMIX; VORTIOXETINE HYDROBROMIDE AMORPHOUS (24.12%).
Core services & business areas
Active ingredients with DMF or CEP filings
Substances for which SIGMAPHARM LABORATORIES LLC holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
SIGMAPHARM LABORATORIES LLC holds 5 active (5 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- VORTIOXETINE HYDROBROMIDE AMORPHOUS (24.12%)Active2017-08-16
- APIXABAN AMORPHOUS (6.58%)Active2016-08-10
- AMORPHOUS DOFETILIDEActive2014-06-05
- ASENAPINE MALEATE AMORPHOUS (31.2%) PREMIXActive2013-08-08
- AMORPHOUS ADEFOVIR DIPIVOXIL (11.6% COPOVIDONE DISPERSION)Active2010-06-03
Registered manufacturing sites (1)
Physical sites registered with the US FDA and resolved to SIGMAPHARM LABORATORIES LLC, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
FDA compliance signals
15 FDA enforcement records linked to this company.
- 4832025-12-17
Extent of discrepancy, failure investigations
- recall — Class II2021-10-06
Failed Impurities/Degradation Specifications; Out of Specification impurity results obtained during routine testing.
- recall — Class II2021-09-01
Failed Impurities Specifications: Out of Specification impurity results obtained during routine testing.
- recall — Class III2021-05-26
Incorrect Product Formulation; product was manufactured with the incorrect Art Cherry Flavor flavoring agent instead of Art Black Cherry Flavor flavoring agent
- recall — Class III2021-05-26
Incorrect Product Formulation; product was manufactured with the incorrect Art Cherry Flavor flavoring agent instead of Art Black Cherry Flavor flavoring agent
- 4832017-06-19
Review of representative number of batches
- 4832014-11-19
Approve or reject procedures or specs
- 4832014-11-19
Acceptance criteria for sampling & testing
- 4832014-11-19
Cleaning / Sanitizing / Maintenance
- 4832014-11-19
Maintenance of Complaint File
- 4832014-11-19
Control procedures to monitor and validate performance
- 4832014-11-19
Annual visual exams of drug products
- recall — Class II2014-05-28
Cross Contamination with Other Products: Four lots of Liothyronine Sodium Tablets, USP 5 mcg are being recalled due to the finding of a potential carryover of trace amounts of a previously manufactured product.
- 4832013-08-13
Incomplete periodic safety report
- 4832013-08-13
Failure to review ADE information
Is this SIGMAPHARM LABORATORIES LLC?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.